Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluzone High-Dose Quadrivalent in Older Adults
NCT03282240Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Efluelda in influenza, sponsored by Sanofi. Started Sep 2017; status: completed.
02
Drugs
Efluelda
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03282240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282240.